iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer

Core Insights - iTeos Therapeutics has appointed Dr. David Feltquate as Chief Medical Officer to oversee clinical development and regulatory strategies [1][2] - The company aims to become a leading oncology firm, leveraging Dr. Feltquate's extensive experience in immuno-oncology [2][3] - iTeos is focused on advancing its pipeline, particularly the TIGIT franchise, to develop innovative therapies for cancer patients [3][4] Company Overview - iTeos Therapeutics is a clinical-stage biopharmaceutical company specializing in immuno-oncology therapeutics [4] - The company utilizes its understanding of tumor immunology to create novel product candidates targeting immunosuppressive pathways [4] - iTeos has three clinical-stage programs aimed at improving clinical outcomes through optimized pharmacologic properties [4] Product Development - Belrestotug (EOS-448/GSK4428859A) is an anti-TIGIT monoclonal antibody designed to enhance antitumor responses [5] - The therapeutic candidate is in development for multiple indications in collaboration with GSK [5]